Full Press Release Details
Zynex, founded in 1996, develops, manufactures and markets non-invasive FDA-CE marked medical devices for pain relief, stroke/spinal cord rehabilitation, and
neurological diagnosis . Products are marketed to physicians through both dedicated sales and independent distribution channels and prescribed to customers . As of December 2013, the company has approximately 150 active field sales representatives
in thirty-eight states. Zynex has five operating groups with a total addressable market opportunity that the company estimates at approximately $7 Billion for its devices; additionally, there is a growth opportunity from its newly formed services
business, Zynex Billing and Consulting.
ZYNEX NEURODIAGNOSTICS (ZND)
ZYNEX MONITORING SOLUTIONS (ZMS)
ZYNEX BILLING AND CONSULTING (ZBC)
Investment Highlights
Select Financials and Facts
| Ticker: | ZYXI | |||
| Closing Price at 12/30/13: | $ | 0.34 | ||
| 52-Week Range: | $ | 0.20-0.70 | ||
| Shares O/S: | 31.0 M | |||
| Est. Public Float: | 13.0M | |||
| Market Cap (12/30/13): | $ | 10.5M | ||
| Insider Ownership: | 60 | % | ||
| Fiscal Year-end: | 12/31 | |||
| 2012 Revenues: | $ | 39.7M |
Balance Sheet Summary
| $ in millions | 9/30/13 | 12/31/12 | ||||||
| Cash & cash equivalents* | 468k | 823k | ||||||
| Current Assets | 19.2M | 21.3M | ||||||
| Current Liabilities | 11.6M | 12.0M | ||||||
| LT Debt | 121k | 114k | ||||||
| Shareholders equity | 9.0M | 12.4M |
| Investor Relations Contact: Hayden IR | Zynex Inc. | Website: | ||||
| Brett Maas: (646) 536-7331 or Peter Seltzberg: (646) 415-8972 | 9990 Park Meadows Drive | www.Zynex.com | ||||
| E-mail: brett@haydenir.com or peter@haydenir.com | Lone Tree, CO 80124 | |||||
| Website: www.haydenir.com | (800) 495-6670 |
Growth Strategy-Divers
Consolidating TENS Segment to Restore Profitability:
Diversification Initiatives underway to Grow Revenues
Pain Cream-Created in-house compound pharmacy (topical pain creams)
Zynex NeuroDiagnostic
Zynex Monitoring Solutions
Zynex Billing and Consulting
Service based revenue
Pain Cream/Compound Pharmacy Facts and FINANCIAL MODEL:
Thomas Sandgaard, Chairman of the Board, President and Chief Executive Officer , since founding the company in 1996. He has previously held
management positions with companies such as ITT, Siemens, GN Danavox, Dataco and Philips. Most of his work has been in the areas of international sales and distribution, technology transfers, mergers and marketing management in the semiconductor,
telecommunications, data communications and medical equipment industries. Mr. Sandgaard has a bachelors degree in electronics engineering from Denmark s Odense University of Engineering and an MBA from Copenhagen Business School.
Anthony Scalese, Chief Financial since September 2010. Mr. Scalese has over 15 years of experience in accounting, finance and operations and has
spent the past 13 years of his career in the high-tech and healthcare industries. Prior to Zynex, served as Chief Financial Officer for Qualmark Corporation, and held management positions at Coram Healthcare (now Apria Healthcare) as well as
Foundation Health Systems (now Healthnet). Mr. Scalese is a Certified Public Accountant licensed in Colorado, received a Masters in Business Administration from the University of Colorado and a Bachelor of Science in Business
Administration-Accounting from Colorado State University.
Robert Bob Cozart, VP of Technical Operations manages Zynex s
Purchasing, Production, Service, Warehouse, Facilities, and Shipping and Receiving departments. Mr. Cozart has over 26 years of management experience in electronics manufacturing, primarily with Class II and Class III medical devices with such
companies as HEI, Colorado Medtech, Pfizer/Valleylab and Medtronic. Mr. Cozart holds an MBA from Creighton University in Omaha and a BS in Business from the University of Colorado in Boulder.
Robert Bird, VP of Sales, is responsible for all domestic sales within the rehabilitation and pain management markets and directs all domestic sales
activities for the Zynex Medical division of Zynex. Mr. Bird has over 20 years of sales and management experience and holds a B.S. Degree in Business Administration from California State University, Hayward.
The foregoing compilation relates to Zynex Inc. (OTCBB:ZYXI) and contains forward-looking statements, which are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. When used in this document, the words
anticipate, believe, estimate, expect and similar expressions as they relate to Zynex or its management, are intended to identify such forward-looking statements. Zynex s actual results,
performance or achievements could differ materially from the results expressed in, or implied by these forward-looking statements. For more detailed information the reader is referred to Zynex s Form 10-K and other related documents filed with
the Securities and Exchange Commission. This does not constitute an offer to buy or sell securities by the Company and is meant purely for informational purposes. Hayden IR, (HIR) its affiliates, officers, directors, subsidiaries and agents have
been compensated by the Company for the creation of this document. HIR has relied upon information received from the Company, which, although believed to be reliable, cannot be guaranteed. This information is not an endorsement of the Company by
HIR. HIR is not responsible for any claims made by the Company. You should independently investigate and fully understand all risks before investing.